| Clinical trial of the anti-PD-L1 antibody BMS-936559 in HIV-1 infected participants on suppressive antiretroviral therapy CL Gay, RJ Bosch, J Ritz, JM Hataye, E Aga, RL Tressler, SW Mason, ... The Journal of infectious diseases 215 (11), 1725-1733, 2017 | 248 | 2017 |
| Enhanced phosphatase activity attenuates α-synucleinopathy in a mouse model KW Lee, W Chen, E Junn, JY Im, H Grosso, PK Sonsalla, X Feng, N Ray, ... Journal of Neuroscience 31 (19), 6963-6971, 2011 | 221 | 2011 |
| In Vitro Antiviral Characteristics of HIV-1 Attachment Inhibitor BMS-626529, the Active Component of the Prodrug BMS-663068 B Nowicka-Sans, YF Gong, B McAuliffe, I Dicker, HT Ho, N Zhou, ... Antimicrobial agents and chemotherapy 56 (7), 3498-3507, 2012 | 174 | 2012 |
| HIV-1 coreceptors and their inhibitors N Ray, RW Doms Chemokines and Viral Infection, 97-120, 2006 | 160 | 2006 |
| Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1–infected subjects RE Nettles, D Schürmann, L Zhu, M Stonier, SP Huang, I Chang, C Chien, ... The Journal of infectious diseases 206 (7), 1002-1011, 2012 | 121 | 2012 |
| Transcriptional response of a common permissive cell type to infection by two diverse alphaherpesviruses N Ray, LW Enquist Journal of virology 78 (7), 3489-3501, 2004 | 115 | 2004 |
| Efficacy and safety of abatacept in active primary Sjögren's syndrome: results of a phase III, randomised, placebo-controlled trial AN Baer, JE Gottenberg, EW St Clair, T Sumida, T Takeuchi, R Seror, ... Annals of the rheumatic diseases 80 (3), 339-348, 2021 | 106 | 2021 |
| Activity of the HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068, against CD4-independent viruses and HIV-1 envelopes resistant to other … Z Li, N Zhou, Y Sun, N Ray, M Lataillade, GJ Hanna, M Krystal Antimicrobial agents and chemotherapy 57 (9), 4172-4180, 2013 | 89 | 2013 |
| Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068 N Zhou, B Nowicka-Sans, B McAuliffe, N Ray, B Eggers, H Fang, L Fan, ... Journal of Antimicrobial Chemotherapy 69 (3), 573-581, 2014 | 84 | 2014 |
| Clinical Resistance to Enfuvirtide Does Not Affect Susceptibility ofHuman Immunodeficiency Virus Type 1 to Other Classes of Entry Inhibitors N Ray, JE Harrison, LA Blackburn, JN Martin, SG Deeks, RW Doms Journal of virology 81 (7), 3240-3250, 2007 | 80 | 2007 |
| HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry JC Tilton, H Amrine-Madsen, JL Miamidian, KM Kitrinos, J Pfaff, ... AIDS research and human retroviruses 26 (1), 13-24, 2010 | 65 | 2010 |
| Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS): development and validation of a novel outcome measure S Arends, L de Wolff, JF van Nimwegen, GMPJ Verstappen, J Vehof, ... The Lancet Rheumatology 3 (8), e553-e562, 2021 | 64 | 2021 |
| Development and preliminary validation of the Sjögren's Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren's … R Seror, G Baron, M Camus, D Cornec, E Perrodeau, SJ Bowman, ... Annals of the rheumatic diseases 81 (7), 979-989, 2022 | 63 | 2022 |
| Prediction of virological response and assessment of resistance emergence to the HIV-1 attachment inhibitor BMS-626529 during 8-day monotherapy with its prodrug BMS-663068 N Ray, C Hwang, MD Healy, J Whitcomb, M Lataillade, M Wind-Rotolo, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 64 (1), 7-15, 2013 | 63 | 2013 |
| Study of Andes virus entry and neutralization using a pseudovirion system N Ray, J Whidby, S Stewart, JW Hooper, A Bertolotti-Ciarlet Journal of virological methods 163 (2), 416-423, 2010 | 62 | 2010 |
| HR-2 mutations in human immunodeficiency virus type 1 gp41 restore fusion kinetics delayed by HR-1 mutations that cause clinical resistance to enfuvirtide N Ray, LA Blackburn, RW Doms Journal of virology 83 (7), 2989-2995, 2009 | 59 | 2009 |
| Maraviroc in the treatment of HIV infection N Ray Drug design, development and therapy, 151-161, 2009 | 51 | 2009 |
| Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities P Pugach, N Ray, PJ Klasse, TJ Ketas, E Michael, RW Doms, B Lee, ... Virology 387 (2), 296-302, 2009 | 47 | 2009 |
| Cyclooxygenase-1 and-2 are required for production of infectious pseudorabies virus N Ray, ME Bisher, LW Enquist Journal of virology 78 (23), 12964-12974, 2004 | 46 | 2004 |
| HLA-DRB1 risk alleles for RA are associated with differential clinical responsiveness to abatacept and adalimumab: data from a head-to-head, randomized, single-blind study in … W Rigby, JH Buckner, S Louis Bridges, M Nys, S Gao, M Polinsky, N Ray, ... Arthritis Research & Therapy 23, 1-13, 2021 | 35 | 2021 |